PMID- 7656335
OWN - NLM
STAT- MEDLINE
DCOM- 19951002
LR  - 20211203
IS  - 0008-8749 (Print)
IS  - 0008-8749 (Linking)
VI  - 164
IP  - 2
DP  - 1995 Sep
TI  - Shared T cell epitopes in epithelial tumors.
PG  - 279-86
AB  - We have previously shown the importance of human leukocyte antigen (HLA)-A2 and 
      the proto-oncogene HER2/neu in the T cell recognition of ovarian cancer. Since 
      these proteins are ubiquitously expressed in epithelial-derived tumors, we have 
      acid-eluted HLA-bound peptides from ovarian cancers, fractionated the peptides, 
      and reconstituted T cell epitopes on the HLA-A2+ T2 cell line to determine if 
      common tumor-associated antigens exist among HLA-A2+, HER2/neu+ epithelial 
      cancers. We demonstrate that tumor-specific cytotoxic T lymphocytes (CTL) 
      generated from tumor-infiltrating lymphocytes isolated from three ovarian, two 
      breast, and two non-small-cell lung cancers recognize at least three of the same 
      peptide fractions from multiple elutions. One of these peptide fractions coelutes 
      with a HER2/neu-derived peptide which has been shown recently to be recognized by 
      these same CTL. These findings demonstrate that a common peptide-based tumor 
      vaccine is theoretically possible for many different epithelial-derived cancers.
FAU - Peoples, G E
AU  - Peoples GE
AD  - Laboratory of Biological Cancer Therapy, Brigham and Women's Hospital, Harvard 
      Medical School, Boston, Massachusetts 02115, USA.
FAU - Smith, R C
AU  - Smith RC
FAU - Linehan, D C
AU  - Linehan DC
FAU - Yoshino, I
AU  - Yoshino I
FAU - Goedegebuure, P S
AU  - Goedegebuure PS
FAU - Eberlein, T J
AU  - Eberlein TJ
LA  - eng
GR  - CA09535/CA/NCI NIH HHS/United States
GR  - R01 CA45484/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Cell Immunol
JT  - Cellular immunology
JID - 1246405
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Peptides)
RN  - 0 (Proto-Oncogene Mas)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antigens, Neoplasm/*immunology
MH  - Breast Neoplasms/*immunology
MH  - Carcinoma, Non-Small-Cell Lung/*immunology
MH  - Epithelium/*immunology
MH  - Female
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - In Vitro Techniques
MH  - Lung Neoplasms/*immunology
MH  - Ovarian Neoplasms/*immunology
MH  - Peptides/*immunology
MH  - Proto-Oncogene Mas
MH  - Receptor, ErbB-2/metabolism
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - S0008-8749(85)71171-9 [pii]
AID - 10.1006/cimm.1995.1171 [doi]
PST - ppublish
SO  - Cell Immunol. 1995 Sep;164(2):279-86. doi: 10.1006/cimm.1995.1171.